The founder of Telo Genomics’ technology is Dr. Sabine Mai. She is the Canada Research Chair (Tier 1) in Genomic Instability and Nuclear Architecture of Cancer. Dr. Mai is also a professor in multiple disciplines and the Director of The Genomic Centre for Cancer Research and Diagnosis, at the University of Manitoba. She has won numerous awards and is an internationally recognized researcher, who has contributed numerous important publications in the field of Genomics and Genomic Instability.
In 1995, Dr. Mai joined the Manitoba Institute of Cell Biology, University of Manitoba (Winnipeg, Canada). She arrived after completing her PhD at the University of Karlsruhe (Germany) and her post-doctoral training at Basel Institute of Immunology (Switzerland) and National Institutes of Health (USA).
In 25 years at the U of M, Dr. Mai has developed the most comprehensive telomere-based platform in the industry. It quantitatively analyzes the correlation between up to six features of telomeres and genomic instability as a predictor of disease. Dr. Mai and her academic lab have raised over $25 million in government funding. The platform is validated with over 140 peer-reviewed publications, 25 clinical studies involving more than 3,000 patients, including 14 different cancers plus Alzheimer’s disease.
Telo Genomics was created to commercialize Dr. Mai’s platform technology. Its lead application is a prognostic tool, for unmet market needs, designed to address multiple stages of multiple myeloma. It is a Canadian incorporated company that trades on the Toronto Venture Stock Exchange (TSX.V: TELO) and with a head office and laboratory at the MaRS Research Centre in Toronto.